Trademark: 97774113
Word
GOFYXIIQ
Status
Pending
Status Code
681
Status Date
Thursday, May 23, 2024
Serial Number
97774113
Mark Type
4
Filing Date
Tuesday, January 31, 2023
Published for Opposition
Tuesday, June 25, 2024

Trademark Owner History

Classifications
5 Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD

Trademark Events
Feb 3, 2023
New Application Entered
Feb 17, 2023
New Application Office Supplied Data Entered
Oct 27, 2023
Assigned To Examiner
Dec 21, 2023
Teas Response To Office Action Received
May 20, 2024
Assigned To Lie
May 21, 2024
Correspondence Received In Law Office
May 21, 2024
Teas/Email Correspondence Entered
May 23, 2024
Approved For Pub - Principal Register
Oct 27, 2023
Non-Final Action Written
Oct 27, 2023
Non-Final Action E-Mailed
Oct 27, 2023
Notification Of Non-Final Action E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24